CS232280B1 - Method of paralell preparation of digoxine and lanatoside c - Google Patents
Method of paralell preparation of digoxine and lanatoside c Download PDFInfo
- Publication number
- CS232280B1 CS232280B1 CS834763A CS476383A CS232280B1 CS 232280 B1 CS232280 B1 CS 232280B1 CS 834763 A CS834763 A CS 834763A CS 476383 A CS476383 A CS 476383A CS 232280 B1 CS232280 B1 CS 232280B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- lanatoside
- digoxin
- chloroform
- foxglove
- drug
- Prior art date
Links
- 229960005156 digoxin Drugs 0.000 title claims abstract description 26
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 title claims abstract description 26
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 title claims abstract description 26
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 title claims abstract description 19
- 229960002614 lanatoside c Drugs 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 8
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims abstract description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 23
- JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000012141 concentrate Substances 0.000 claims abstract description 16
- 229930182470 glycoside Natural products 0.000 claims abstract description 15
- 150000002338 glycosides Chemical class 0.000 claims abstract description 15
- 241000208011 Digitalis Species 0.000 claims abstract description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002955 isolation Methods 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- OAABHEHWRQAHEJ-UHFFFAOYSA-N butan-1-ol;chloroform Chemical compound ClC(Cl)Cl.CCCCO OAABHEHWRQAHEJ-UHFFFAOYSA-N 0.000 claims description 2
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 12
- 210000002268 wool Anatomy 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229960003304 acetyldigoxin Drugs 0.000 description 9
- HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 description 9
- MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- YFGQJKBUXPKSAW-UHFFFAOYSA-N Lanatosid A Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)CC4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O YFGQJKBUXPKSAW-UHFFFAOYSA-N 0.000 description 2
- YFGQJKBUXPKSAW-YSTAXILLSA-N Lanatoside A Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFGQJKBUXPKSAW-YSTAXILLSA-N 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- NIVHSKHPHHRBAM-UHFFFAOYSA-N Diginatin Natural products CC1OC(CC(O)C1O)OC2CCC3(C)C(CCC4C3CC(O)C5(C)C(C(O)CC45O)C6=CC(=O)OC6)C2 NIVHSKHPHHRBAM-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- -1 GDR pat. 70 Chemical compound 0.000 description 1
- OCEDEAQHBIGPTE-UHFFFAOYSA-N Gitoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CCOC8=O)C4)OC3C)OC2C OCEDEAQHBIGPTE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229930188389 Lanatoside Natural products 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- AASCKLXRKILUGL-UHFFFAOYSA-N diginateyne Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CC(O)C(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O AASCKLXRKILUGL-UHFFFAOYSA-N 0.000 description 1
- AASCKLXRKILUGL-KDVLELMDSA-N diginatin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(C[C@H](O)[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O AASCKLXRKILUGL-KDVLELMDSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950000974 gitoxin Drugs 0.000 description 1
- LKRDZKPBAOKJBT-CNPIRKNPSA-N gitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(C[C@H](O)[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LKRDZKPBAOKJBT-CNPIRKNPSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Abstract
Digoxin a lanatosid C jsou důležitá léčiva získávaná izolací z drogy náprstníku vlnatého. Postup podle vynálezu ekonomizuje výrobu lanatosidu C tím, že umožňuje izolovat digoxin, který je vždy v droze obsažen vedle lanatosidu C. Současná izolace lanatosidu C a digoxinu je dosaženo postupnou extrakcí vodného koncentrátu glykosidů náprstníku vlnatého etherem, chloroformem nebo dichlormethanem a směsí chloroformu s 5 až 30 objemovými procenty n-butanolu nebo isopropylalkoholu.Digoxin and lanatoside C are important drugs obtained by isolation from the foxglove drug wool. The process of the invention economizes producing lanatoside C by allowing isolation digoxin, which is always contained in the drug in addition to lanatoside C. Simultaneous isolation of lanatoside C and digoxin is achieved gradually by extracting an aqueous concentrate of the foxglove glycoside with ether, chloroform, or with dichloromethane and chloroform with 5 to 30 percent by volume n-butanol or isopropyl alcohol.
Description
Vynález se týká současná izolace digoxinu a lanatosidu C z vodného koncentrátu glykosidu.náprstníku vlnatáho (digitelis lanate E HRH). Pojmem vodný koncentrát glykosidů označujeme vodný roztok glykosidů náprstníku vlnatáho a balastních látek, připravený o sobě známými postupy z drogy náprstníku vlnatáho, zejména extrakcí drogy vodným methanolem a odpařením methanolu. Vodný koncentrát obsahuje v závislosti na kvalitě výchozí drogy a způsobu extrakce 0,05 až 0,5 % lanatoxidu C a 0,05 až 0,6 % potenciálního digoxinu (vis dále).SUMMARY OF THE INVENTION The present invention relates to the simultaneous isolation of digoxin and lanatoside C from an aqueous concentrate of a glycoside of a foxglove (digitelis lanate E HRH). The term aqueous glycoside concentrate refers to an aqueous solution of glycosides of foxglove and ballasts prepared by known methods from the foxglove drug, in particular by extracting the drug with aqueous methanol and evaporating methanol. The aqueous concentrate contains, depending on the quality of the starting drug and the method of extraction, 0.05 to 0.5% of lanatoxide C and 0.05 to 0.6% of potential digoxin (see below).
Lanatosid C a digoxin jsou terapeuticky nejžádanější z glykosidů náprstníku, Eanatosíd C je tav. primární glykosid, digoxin je sekundární glykosid odvozený od lanatosidu C. Odštěpením molekuly glukózy účinkem glukozidázy vzniká acetyldigoxin, který odštěpením acetylová skupiny účinkem' esterázy přechází na digoxin. Proto droga náprstníku vlnatáho obsahuje vedle sebe lanatosid C, digoxin a acetyldigoxin. Vzájemný poměr těchto látek kolísá v závislosti ne způsobu posklizňová úpravy drogy. Směs acetyldigoxinu a digoxinu označujeme ve vynálezu jako potenciální digoxin, protože acetyldigoxin lze chemicky odbourat ne digoxin (např. NDR pat. 70 088).Lanatoside C and digoxin are therapeutically most desirable of the foxglove glycosides, Eanatoside C is a melt primary glycoside, digoxin is a secondary glycoside derived from lanatoside C. Cleavage of the glucose molecule by glucosidase produces acetyldigoxin, which converts the acetyl group by digoxin esterase. Therefore, the foxglove drug contains side-by-side lanatoside C, digoxin and acetyldigoxin. The proportion of these substances varies depending on the post-harvest treatment of the drug. The mixture of acetyldigoxin and digoxin is referred to as a potential digoxin in the invention, since acetyldigoxin can be chemically degraded to digoxin (e.g., GDR pat. 70,088).
Droga náprstníku vlnatáho se používá buá pro výrobu lanatosidu C nebo digoxinu. V případě výroby digoxinu se droga podrobí fermentačnímu procesu při němž se lanatosid C a acetyldigoxin převedou na digoxin a ten se isoluje (USA pat. 2 534 260, NSR pat. 2 932 577,The foxglove drug is used either for the production of lanatoside C or digoxin. In the case of digoxin production, the drug is subjected to a fermentation process in which lanatoside C and acetyldigoxin are converted to digoxin and isolated therefrom (U.S. Pat. No. 2,534,260, Germany Pat. No. 2,932,577,
NSR pat. 1 183 627, Franc. pat. 6 222 M).NSR pat. 1 183 627, Franc. U.S. Pat. 6,222 M).
Při izolaci lanatosidu C se droga přímo extrahuje vhodnými polárními rozpouštědly a se získaného extraktu se isoluje lanatosid C (Helv. Chim. Acta 16. 1 049 /1933/; Helv. Chim. Acta 2Í *3 /1942/; NDR.pat. 42 345; SSSR pat. 205 228; čs. autorské osvědčení č. 219 423). Při věech těchto postupech se izoluje pouze lanatosid C, kdežto digoxin e acetyldigoxin, která jsou rovněž přítomny ve výchozí surovině se nevyužívají a odpadají z výroby ve formě těžko dělitelných směsí látek.In the isolation lanatoside C, the drug is directly extracted by appropriate polar solvent and the extract obtained is isolated lanatoside C (Helv. Chim. Acta 16th 1049/1933 /; Helv. Chim. Acta, 2 R * 3/1942 /; NDR.pat. 42 345; USSR Pat. 205 228; Czechoslovakian Author's Certificate No. 219 423). In all of these processes, only lanatoside C is isolated, whereas digoxin and acetyldigoxin, which are also present in the starting material, are not used and fall off from production in the form of hardly separable mixtures of substances.
Postup podle vynálezu tento zásadní nedostatek odstraňuje. Umožňuje získat z vodného koncentrátu glykosidů náprstníku vlnatáho frakci obsahující sekundární glykosidy a tedy potenciální digoxin a frakci obsahující primární glykosidy, zejména lanatoxid C. Bylo zjiěteno, že vodný koncentrát glykosidů získaný extrakcí drogy náprstníku vlnatáho 80 až 95* vodným methanolem a odpařením methenolu tak, aby jeho obsah byl 0 až 20 *, lze výhodně extrahovat postupně etherem, chloroformem nebo dichlormethenem e směsí chloroformu s 5 až 30 objemovými procenty n-butanolu nebo isopropylelkoholu. Přitom do etherového extraktu přecházejí zejména nepolární balastní látky a podstatná část acetyldlgitoxinu. Digoxin vůbec do etherového roztoku nepřichází, acetyldigoxin přichází v množství maximálně 5 * ze sumy této látky ve vodném koncentrátu. Do chloroformového nebo dichlormethenováho extraktu přechází vedle balastních látek prakticky všechen acetyldigoxin a digoxin a déle digitoxin, gitoxin a diginatin, část lanatosidu A a menší množství dalších, blíže neurče ných glykosidů néprstrfkuu vlnatáho. Získaná frakce sekundárních glykosidů se zpracuje o sobě známými postupy na digoxin. Lanatoxid C do chloroformového nebo methylenchloridového extraktu vůbec nepřichází, ele extrahuje se v následujícím stupni chloroformem polarizovaným přídavkem výše uvedeného alkoholu. Tento extrakt obsahuje kromě lanatosidu C zbytek lanatosidu A, lanatosidy B a D, dezacetylenatosidy a řadu balastů. Takto získaná frakce primárních glykosidů se zpracuje o sobě známými postupy na lanatosid C s výhodou podle čs. autorského osvědčení 6. 219 423.The process according to the invention removes this fundamental drawback. It makes it possible to obtain a fraction containing secondary glycosides and thus a potential digoxin and a fraction containing primary glycosides, in particular lanatoxide C, from the aqueous concentrate of the foxglove of the foxglove. It was found that the aqueous glycoside concentrate obtained by extracting the foxglove drug by 80-95 * with methanol and evaporating the methanol its content is 0 to 20%, it can be advantageously extracted successively with ether, chloroform or dichloromethane and with a mixture of chloroform with 5 to 30% by volume of n-butanol or isopropyl alcohol. In particular, non-polar ballast substances and a substantial part of acetyldgitoxin pass into the ether extract. Digoxin does not enter the ether solution at all, acetyldigoxin comes in at most 5% of the sum of this substance in the aqueous concentrate. Almost all acetyldigoxin and digoxin and, for some time, digitoxin, gitoxin and diginatin, a part of lanatoside A and a smaller amount of other undetermined glycosides of undiluted silver are transferred into the chloroform or dichloromethane extract. The obtained secondary glycoside fraction is processed to digoxin by known methods. Lanatoxide C does not come into the chloroform or methylene chloride extract at all, but is extracted in the next step with chloroform polarized by the addition of the above alcohol. In addition to lanatoside C, this extract contains the remainder of lanatoside A, lanatosides B and D, desacetylenatosides and a number of ballasts. The fraction of primary glycosides thus obtained is processed to lanatoside C by known methods, preferably according to U.S. Pat. of the certificate 6. 219 423.
Příklad' ,00 litrů vodného koncentrátu glykosidů náprstníku vlnatáho, který obsahuje 5 % methanolu; 0,105 % lanatosidu C; 0,035 % digoxinu a 0,064 % acetyldigoxinu se extrahuje etherem na protiproudovém vibračním extraktoru o průměru 105 mm a délce 4 m. Nétok vodného koncentrátu je 100 l.h~\ nátok etheru 40 l.h~\ Rafinovaný vodný koncentrát se potom zbaví etheru na filmové odparce a extrahuje se na stejném vibračním extraktoru chloroformem:Example 100 liters of an aqueous glycoside concentrate of a foxglove containing 5% methanol; 0.105% lanatoside C; 0.035% digoxin and 0.064% acetyldigoxin are extracted with ether on a counter-current vibration extractor with a diameter of 105 mm and a length of 4 m. The aqueous concentrate inlet is 100 liters of ether 40 liters. The refined aqueous concentrate is then dehydrated on a film evaporator and extracted on the same vibration extractor with chloroform:
nátok vodného koncentrátu je 100 l.h-', nátok chloroformu je 33 l.h“'. Chloroformový extrakt se zahustí na sušinu 20 až 30 %. Tento materiál obsahuje 80 až 90 % potenciálního digoxinu obsaženého ve vodném koncentrátu a použije se k izolaci digoxinu. Chloroformem raginovaný vodný koncentrát se potom extrahuje na stejném vibračním extraktoru chloroformem s 10 objemovými procenty n-butanolu. Nátok lehké fáze je 100 l.h-1, nátok těžké fáze je 80 l.h-'. Získaný chloroform-butanolový extrakt obsahuje 85 až 95 % lenatosidu C původně přítomného ve vodném koncentrátu a použije se k výrobě lanatoaidu C.the inlet of the aqueous concentrate is 100 lh - ', the inlet of chloroform is 33 lh''. The chloroform extract is concentrated to dryness of 20 to 30%. This material contains 80 to 90% of the potential digoxin contained in the aqueous concentrate and is used to isolate digoxin. The chloroform-raginated aqueous concentrate is then extracted on the same vibration extractor with chloroform with 10% by volume of n-butanol. The light phase inlet is 100 lh -1 , the heavy phase inlet is 80 lh - '. The chloroform-butanol extract obtained contains 85 to 95% of the lenatoside C initially present in the aqueous concentrate and is used to produce lanatoid C.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS834763A CS232280B1 (en) | 1983-06-27 | 1983-06-27 | Method of paralell preparation of digoxine and lanatoside c |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS834763A CS232280B1 (en) | 1983-06-27 | 1983-06-27 | Method of paralell preparation of digoxine and lanatoside c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS476383A1 CS476383A1 (en) | 1984-05-14 |
| CS232280B1 true CS232280B1 (en) | 1985-01-16 |
Family
ID=5391116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS834763A CS232280B1 (en) | 1983-06-27 | 1983-06-27 | Method of paralell preparation of digoxine and lanatoside c |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS232280B1 (en) |
-
1983
- 1983-06-27 CS CS834763A patent/CS232280B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS476383A1 (en) | 1984-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawai et al. | Studies on the saponins of Lonicera japonica Thunb | |
| Sakamura et al. | Conjugated serotonins and phenolic constituents in safflower seed (Carthamus tinctorius L.) | |
| Harmatha et al. | Identification of a spirostane-type saponin in the flowers of leek with inhibitory effects on growth of leek-moth larvae | |
| Lavaud et al. | Triterpene saponins Frommyrsine pellucida | |
| Pistelli et al. | Triterpenoid saponins from Bupleurum fruticosum | |
| ZHANG et al. | Studies on the Constituents of Asclepiadaceae Plants. LXI. The Structure of Cynatratoside-F from the Chinese Drug" Pai-Wei," Dried Root of Cynanchum atratum BUNGE | |
| Tupkari et al. | Phytochemical study of Solanum xanthocarpum | |
| RU2206572C1 (en) | Method of isolation of betulinol | |
| Roby et al. | Penstemonoside and other iridoids from Castilleja rhexifolia. Conversion of penstemonoside to the pyridine monoterpene alkaloid rhexifoline | |
| Boonsong et al. | The cardiac glycosides present in mistletoes growing on Nerium oleander | |
| CS232280B1 (en) | Method of paralell preparation of digoxine and lanatoside c | |
| Iwamoto et al. | Studies on the Constituents of Actinostemma lobatum MAXIM. I Structures of Actinostemmosides A, B, C and D, Dammarane Triterpene Glycosides Isolated from the Herb | |
| Sakuma et al. | Constituents of Chinese Crude Drug" Wujiapi." I. Studies on the Aglycones of Steroidal Glycosides of Pei-wujiapi.(1) | |
| Van Oycke et al. | New cardenolide glycosides from the defence glands of Chrysolinina beetles (Coleoptera: Chrysomelidae) | |
| Sakagami et al. | Isolation and structure of medicarpin-β-D-glucoside in alfalfa | |
| Evidente | Identification of 11-hydroxyvittatine in Sternbergia lutea | |
| Zhang et al. | Chantriolide C, a new withanolide glucoside and a new spirostanol saponin from the rhizomes of Tacca chantrieri | |
| Gonzalez et al. | Phytochemical study of Isoplexis chalcantha | |
| Kitajima et al. | New Monoterpenoid and Hemiterpenoid Tetraol of the Crude Drug" She chuang zi" | |
| Marston et al. | Analysis and isolation of saponins from plant material | |
| Tompkins et al. | Syntheses of amino sugars from tri-O-acetyl-D-glucal via epoxides | |
| Cho et al. | Triterpenoidal saponins from the bark of Kalopanax pictum var. typicum | |
| NAGUMO et al. | Cyanogenic glycosides and 4-hydroxycoumarin glycosides from Gerbera jamesonii hybrida | |
| Lee et al. | Triterpenoidal saponins from the leaves of Kalopanax pictum var. chinense | |
| US2552896A (en) | Methanol extraction of cascara sagrada bark |